Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

Cancer Gene Therapy

Volumn 14, Issue 1, 2007, Pages 105-116

  Takayama, K ^a,b   Reynolds, P N ^a,c   Adachi, Y ^a   Kaliberova, L ^a   Uchino, J ^b   Nakanishi, Y ^b   Curiel, D T ^a,d  

^a University of Alabama at Birmingham   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Angiogenesis; Chimeric vector; Replicative adenovirus; VEGF

Indexed keywords

ADENOVIRUS VECTOR; GLYCOPROTEIN E1; PROTEIN P53; VASCULOTROPIN; VASCULOTROPIN E1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CARCINOMA; CELL KILLING; CELL TYPE; CONDITIONALLLY REPLICATIVE ADENOVIRUS; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; BASE SEQUENCE; DNA PRIMERS; GENE THERAPY; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 33845640114     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700991     Document Type: Article

References (45)

1. Levi F, Lucchini F, Negri E, La Vecchia C. Worldwide patterns of cancer mortality, 1990-1994. Eur J Cancer Prev 1999; 8: 381-400.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
3. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
4. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996; 2: 1411-1416.
5. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3: 861-865.
6. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 8: 3480-3486.
7. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-8800.
8. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000; 60: 2169-2177.
9. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000; 6: 3395-3399.
10. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
11. Fueyo J, Comez-Manzano C, Alemany R, Lee PSY, McDonell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 1999; 19: 1-11.
12. Hallenbeck PL, Chang Y-N, Hay C, Golightly D, Stewart D, Lin J et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
13. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replacation competent adenovirus (ARCA) CV706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
14. Matsubara S, Wada Y, Gardner TA, Egawa M, Park M-S, Hsieh C-L et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001; 61: 6012-6019.
15. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
16. Adachi Y, Reynolds PN, Yamamoto M, Wang M, Takayama K, Matsubara S et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001; 61: 7882-7888.
17. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663-4670.
18. DeWeese TL, Van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472.
19. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55KD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res 2000; 60: 6359-6366.
20. He T-C, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating reombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
21. Forsythe JA, Jiang B-H, Iyer NV, Agani E, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor I. Mol Cell Biol 1996; 16: 4604-4613.
22. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839-6846.
23. Takayama K, Ueno H, Pei X-H, Nakanishi Y, Yatsunami J, Hara N. The levels of integrin αvβ5 may predict the susceptibility to adenovirus-mediated gene transfer in human lung cancers. Gene Therapy 1998; 5: 361-368.
24. Maizel JVJ, White O, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968; 36: 115-125.
25. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
26. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810.
27. Kaliberov S, Buchsbaum D, Gillespie G, Curiel DT, Arafat W, Carpenter M et al. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther 2002; 6: 190-198.
28. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126.
29. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
30. Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002; 62: 4273-4281.
31. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105: 1169-1172.
32. Heise CC, Williams A, Olesch J, Kirn DH. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 1999; 6: 499-504.
33. van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FHE, van Krieken JHM, van der Eb AJ et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy 1998; 5: 451-458.
34. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002; 9: 36-44.
35. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336-340.
36. Yuan A, Yu C-J, Chen W-J, Lin F-Y, Kuo S-H, Luh K-T et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000; 89: 475-483.
37. Mall JW, Schwenk W, Philipp AW, Meyer-Kipker C, Mall W, Muller J et al. Serum vascular endothelial growth factor levels correlate better with tumor stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 2002; 7: 99-102.
38. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
39. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 alpha in clear cell renal carcinoma. Cancer Res 2001; 61: 5215-5222.
40. Haviv YS, Takayama K, Glasgow JN, Blackwell JL, Wang M, Lei X et al. A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene. Mol Cancer Ther 2002; 1: 321-328.
41. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-5748.
42. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363-2373.
43. Cripe TP, Dunphy EJ, Holub A, Vasi NH, Mahller YY, Collins MH et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61: 2951-2960.
44. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031-5036.
45. Lam JT, Kanerva A, Bauershcmitz GJ, Takayama K, Suzuki K, Yamamoto M et al. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med 2004; 6: 1333-1342.